ClinicalTrials.gg
CompletedNCT03796676JADE TEENUpdated Apr 13, 2022Results posted

JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis

A Phase 3 interventional study of Placebo and PF-04965842 in Atopic Dermatitis, sponsored by Pfizer. Completed at 136 sites in 14 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2022-04-13.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
287
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing abrocitinib in Dermatitis, Atopic — 5 open to participants now, 5 under way, 2 of them phase 3. abrocitinib · Dermatitis, Atopic.

Enrollment
8th of 20
287 · median 150
Started
2019
with 1 other
Phase 3
10 of 20
2 open now
Registered
8th of 20
by date
Lead sponsor
15 of 20
Pfizer

Among the 20 studies testing abrocitinib in Dermatitis, Atopic, this one is the 8th largest by enrollment, is one of 2 that started in 2019, is one of 10 in phase 3, and was the 8th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

5 of the 20 studies testing abrocitinib in Dermatitis, Atopic are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About abrocitinib

abrocitinib: first FDA approval 2022 (CIBINQO), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing abrocitinib in Dermatitis, Atopic, or all of them as a file.
02

Study summary

This is a randomized, double blind, placebo controlled, parallel group, Phase 3 study to evaluate the efficacy and safety of PF 04965842 in adolescent participants 12 to \<18 years of age with moderate to severe AD.

Read the detailed description

This is a randomized, double blind, placebo controlled, parallel group, Phase 3 study to evaluate the efficacy and safety of PF 04965842 in adolescent participants 12 to \<18 years of age with moderate to severe AD. Participants will be screened within 28 days prior to the first dose of study intervention to confirm study eligibility. Subjects must have moderate-severe AD involving at least 10% Body Surface Area (BSA); an Investigator Global Assessment (IGA) score of at least 3; an Eczema Area Severity Index (EASI) of at least 16 and Peak Pruritus Numerical Rating Score (NRS) of at least 4 on baseline/Day 1. Eligible subjects will be randomized at the Baseline/Day 1 visit. Approximately 225 participants will be randomized in a 1:1:1 ratio to receive once daily PF 04965842 at 200 mg, 100 mg, or placebo for 12 weeks. Randomization will be stratified by baseline disease severity (moderate [IGA = 3] vs. severe [IGA = 4] AD). The investigational products will be administered QD for 12 weeks. Background therapy (medicated and non-medicated topical therapy) must be applied BID for the duration of the treatment period. The co-primary efficacy endpoints are an IGA score of clear (0) or almost clear (1) with a reduction from baseline of greater than 2 points at Week 12 AND an at least 75% improvement of the EASI score (EASI-75) at week 12. Safety and efficacy assessments will be conducted at the investigator site by a clinical assessor blinded to treatment assignment. Scheduled clinic or telephone study visits for all subjects will occur at Screening, Baseline/Day 1, Day 8 (by phone), Day 15, Day 29, Day 43 (by phone), Day 57, Day 85 (End of treatment/Early termination), Day 113 (End of Study). Participants discontinuing early from the study will undergo a 4 week follow up period.

This study includes an immunogenicity sub study integrated into the last 4 weeks of the main study treatment period. At Week 8, up to approximately 90 participants (up to approximately 30 in each treatment arm) who have completed 8 weeks of treatment with study intervention will receive a tetanus, diphtheria and acellular pertussis combination vaccine (Tdap), and collection of blood samples for the evaluation of immunogenicity at Weeks 8 and 12. Participants of this sub study will complete all other protocol specified procedures in the main study.

At the end of the 12 week study treatment, qualified participants completing the study will have the option to enter the long term extension (LTE) study B7451015.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

Keywords

  • Atopic Dermatitis, JAK1 inhibitor
04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 12 and to 17 with a minimum body weight of 40 kg
  • Diagnosis of atopic dermatitis (AD) for at least 1 year and current status of moderate to severe disease (>= the following scores: BSA 10%, IGA 3, EASI 16, Pruritus NRS severity 4)

Exclusion criteria

Exclusion Criteria:

  • Acute or chronic medical or laboratory abnormality that may increase the risk associated with study participation
  • Unwilling to discontinue current AD medications prior to the study or require treatment with prohibited medications during the study
  • Prior treatment with JAK inhibitors
  • Other active non-AD inflammatory skin diseases or conditions affecting skin
  • Medical history including thrombocytopenia, coagulopathy or dysfunction, , current or history of certain infections, lymphoproliferative disorders and other medical conditions at the discretion of the investigator
  • Pregnant or breastfeeding women, or women of who are unwilling to use
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
287 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

  • Experimental
    PF-04965842 100 mg QD

    active

    Drug: PF-04965842

  • Experimental
    PF-04965842 200 mg QD

    active

    Drug: PF04965842

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of 'Clear' (0) or 'Almost Clear' (1) and ≥2 Points Improvement From Baseline at Week 12

    The IGA of Atopic Dermatitis (AD) was scored on a 5-point scale (0-4), reflecting a global consideration of the erythema, induration and scaling. The overall severity of AD was assessed according to the 5-point scale: 0=Clear, 1=Almost Clear, 2=Mild, 3=Moderate, and 4=Severe. Participants who withdrew from the study were counted as non-responder.

    Time frame: Baseline to Week 12

  2. Percentage of Participants Achieving Eczema Area and Severity Index (EASI) Response ≥ 75% Improvement From Baseline at Week 12

    The EASI quantifies the severity of AD based on both severity of lesion clinical signs and the percent of body surface area (BSA) affected. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD. Participants who withdrew from the study were counted as non-responder.

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Percentage of Participants Achieving ≥4 Points Improvement From Baseline in Peak Pruritis Numeric Rating Scale (PP-NRS) for Severity of Pruritus at Weeks 2, 4 and 12

    PP-NRS assesses the severity of itch (pruritus) due to AD. Participants were asked to assess their worst itching due to AD on an NRS anchored by the terms "no itch" (0) and "worst itch imaginable" (10). Participants who withdrew from the study were counted as non-responder.

    Time frame: Baseline, Weeks 2, 4 and 12

  2. Change From Baseline in Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) at Week 12

    The PSAAD is a daily patient reported symptom diary presented as a 15 item questionnaire that includes 11 items developed to measure symptoms of AD, along with 4 additional items for exploratory and psychometric validation purposes (Sleep \& Usual Activities Questions and Patient Global Impression of Severity \& Patient Global Impression of Change Questions). Participants answer each question about skin condition based on a 24 hour recall. Each question was evaluated on a 11-point scale ranging from 0 to 10, where higher scores indicate more impact on skin condition.The PSAAD total score is calculated as the average of the responses to each of the 11 items and ranges from 0 (none) to 10 (extreme), where higher scores indicate worse severity of AD symptoms.

    Time frame: Baseline to Week 12

  3. Percentage of Participants Achieving IGA Response of 'Clear' or 'Almost Clear' and ≥2 Points Improvement From Baseline at All Scheduled Time Points Except Week 12

    The IGA of AD is scored on a 5-point scale (0-4), reflecting a global consideration of the erythema, induration and scaling. The overall severity of AD was assessed according to the 5-point scale: 0=Clear, 1=Almost Clear, 2=Mild, 3=Moderate, and 4=Severe. Participants who withdrew from the study were counted as non-responder.

    Time frame: Baseline, Weeks 2, 4 and 8

  4. Percentage of Participants Achieving EASI Response ≥ 75% Improvement From Baseline at All Scheduled Time Points Except Week 12

    The EASI quantifies the severity of AD based on both severity of lesion clinical signs and the percent of BSA affected. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD. Participants who withdrew from the study were counted as non-responder.

    Time frame: Baseline, Weeks 2, 4 and 8

  5. Percentage of Participants Achieving EASI Response ≥ 50% Improvement From Baseline

    The EASI quantifies the severity of AD based on both severity of lesion clinical signs and the percent of BSA affected. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD. Participants who withdrew from the study were counted as non-responder.

    Time frame: Baseline, Weeks 2, 4, 8 and 12

  6. Percentage of Participants Achieving EASI Response ≥ 90% Improvement From Baseline

    The EASI quantifies the severity of AD based on both severity of lesion clinical signs and the percent of BSA affected. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD. Participants who withdrew from the study were counted as non-responder.

    Time frame: Baseline, Weeks 2, 4, 8 and 12

  7. Percentage of Participants Achieving EASI Response =100% Improvement From Baseline

    The EASI quantifies the severity of AD based on both severity of lesion clinical signs and the percent of BSA affected. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD. Participants who withdrew from the study were counted as non-responder.

    Time frame: Baseline, Weeks 2, 4, 8 and 12

  8. Percent Change From Baseline in EASI Score

    The EASI quantifies the severity of AD based on both severity of lesion clinical signs and the percent of BSA affected. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD. Participants who withdrew from the study were counted as non-responder.

    Time frame: Baseline, Weeks 2, 4, 8 and 12

  9. Percentage of Participants Achieving ≥4 Points Improvement From Baseline in PP-NRS for Severity of Pruritus at All Scheduled Time Points Other Than Weeks 2, 4 and 12

    PP-NRS assesses the severity of itch (pruritus) due to AD. Participants were asked to assess their worst itching due to AD on an NRS anchored by the terms "no itch" (0) and "worst itch imaginable" (10). Participants who withdrew from the study were counted as non-responder.

    Time frame: Baseline, Days 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15

  10. Time to First Achieve ≥4 Points Improvement From Baseline in PP-NRS for Severity of Pruritus

    PP-NRS assesses the severity of itch (pruritus) due to AD. Participants were asked to assess their worst itching due to AD on an NRS anchored by the terms "no itch" (0) and "worst itch imaginable" (10).

    Time frame: Baseline to Week 16

  11. Percent Change From Baseline in PP-NRS for Severity of Pruritus

    PP-NRS assesses the severity of itch (pruritus) due to AD. Participants were asked to assess their worst itching due to AD on an NRS anchored by the terms "no itch" (0) and "worst itch imaginable" (10).

    Time frame: Baseline, Days 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15

  12. Change From Baseline in Percentage Body Surface Area (BSA)

    BSA efficacy is derived from the sum of the BSA in handprints across 4 body regions assessed as part of the EASI assessment. Handprint refers to that of each individual participant for their own measurement. The BSA efficacy ranges from 0 to 100%, with higher values representing greater severity of AD. The percentage BSA ranges from 0 to 100, with higher scores representing greater severity of AD. Since the scalp, palms, and soles were excluded from the BSA (efficacy) assessment, the maximum possible percentage BSA was less than 100.

    Time frame: Baseline, Weeks 2, 4, 8 and 12

  13. Percent Change From Baseline in Percentage BSA

    BSA efficacy is derived from the sum of the BSA in handprints across 4 body regions assessed as part of the EASI assessment. Handprint refers to that of each individual participant for their own measurement. The BSA efficacy ranges from 0 to 100%, with higher values representing greater severity of AD. The percentage BSA ranges from 0 to 100, with higher scores representing greater severity of AD. Since the scalp, palms, and soles were excluded from the BSA (efficacy) assessment, the maximum possible percentage BSA was less than 100.

    Time frame: Baseline, Weeks 2, 4, 8 and 12

  14. Percentage of Participants Achieving Percentage BSA < 5% at Week 12

    BSA efficacy is derived from the sum of the BSA in handprints across 4 body regions assessed as part of the EASI assessment. Handprint refers to that of each individual participant for their own measurement. The BSA efficacy ranges from 0 to 100%, with higher values representing greater severity of AD. The percentage BSA ranges from 0 to 100, with higher scores representing greater severity of AD. Since the scalp, palms, and soles were excluded from the BSA (efficacy) assessment, the maximum possible percentage BSA was less than 100.

    Time frame: Baseline to Week 12

  15. Percentage of Participants Achieving Scoring Atopic Dermatitis (SCORAD) Response ≥ 50% Improvement From Baseline

    SCORAD is a validated scoring index for AD,which combines extent (0-100),severity (0-18),and subjective symptoms (0-20) based on pruritus and sleep loss,each scored (0-10). Extent,denoted as A,is measured by BSA affected by AD as a percentage of the whole BSA.The score for each body region is added up to determine A (maximum of 100).Severity, denoted as B,consists of the severity of several signs.Each is assessed as none(0),mild(1),moderate(2) or severe(3).The severity scores are added together to give B (maximum of 18).Subjective symptoms,denoted as C,are each scored by the participant using a NRS where "0" is no itch (or no sleeplessness) and "10" is the worst imaginable itch (or sleeplessness).These scores are added to give 'C' (maximum of 20).SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103).Higher values of SCORAD represent worse outcome.

    Time frame: Baseline, Weeks 2, 4, 8 and 12

  16. Percentage of Participants Achieving SCORAD Response ≥ 75% Improvement From Baseline

    SCORAD is a validated scoring index for AD,which combines extent (0-100),severity (0-18),and subjective symptoms (0-20) based on pruritus and sleep loss,each scored (0-10). Extent,denoted as A,is measured by BSA affected by AD as a percentage of the whole BSA.The score for each body region is added up to determine A (maximum of 100).Severity, denoted as B,consists of the severity of several signs.Each is assessed as none(0),mild(1),moderate(2) or severe(3).The severity scores are added together to give B (maximum of 18).Subjective symptoms,denoted as C,are each scored by the participant using a NRS where "0" is no itch (or no sleeplessness) and "10" is the worst imaginable itch (or sleeplessness).These scores are added to give 'C' (maximum of 20).SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103).Higher values of SCORAD represent worse outcome.

    Time frame: Baseline, Weeks 2, 4, 8 and 12

  17. Change From Baseline in SCORAD Total Score

    SCORAD is a validated scoring index for AD,which combines extent (0-100),severity (0-18),and subjective symptoms (0-20) based on pruritus and sleep loss,each scored (0-10). Extent,denoted as A,is measured by BSA affected by AD as a percentage of the whole BSA.The score for each body region is added up to determine A (maximum of 100).Severity, denoted as B,consists of the severity of several signs.Each is assessed as none(0),mild(1),moderate(2) or severe(3).The severity scores are added together to give B (maximum of 18).Subjective symptoms,denoted as C,are each scored by the participant using a NRS where "0" is no itch (or no sleeplessness) and "10" is the worst imaginable itch (or sleeplessness).These scores are added to give 'C' (maximum of 20).SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103).Higher values of SCORAD represent worse outcome.

    Time frame: Baseline, Weeks 2, 4, 8 and 12

  18. Percent Change From Baseline in SCORAD Total Score

    SCORAD is a validated scoring index for AD,which combines extent (0-100),severity (0-18),and subjective symptoms (0-20) based on pruritus and sleep loss,each scored (0-10). Extent,denoted as A,is measured by BSA affected by AD as a percentage of the whole BSA.The score for each body region is added up to determine A (maximum of 100).Severity, denoted as B,consists of the severity of several signs.Each is assessed as none(0),mild(1),moderate(2) or severe(3).The severity scores are added together to give B (maximum of 18).Subjective symptoms,denoted as C,are each scored by the participant using a NRS where "0" is no itch (or no sleeplessness) and "10" is the worst imaginable itch (or sleeplessness).These scores are added to give 'C' (maximum of 20).SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103).Higher values of SCORAD represent worse outcome.

    Time frame: Baseline, Weeks 2, 4, 8 and 12

  19. Change From Baseline in SCORAD Subjective Visual Analogue Scale (VAS) of Sleep Loss

    SCORAD is a validated scoring index for AD, which combines extent (A, 0-100), severity (B, 0-18), and subjective symptoms (C, 0-20) based on pruritus and sleep loss, each scored (0-10). The SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103). Subjective symptoms (ie, itch and sleep loss) are each scored by the participant using a VAS where "0" is no itch (or no sleep loss) and "10" is the worst imaginable itch (or sleep loss). The value for each should reflect the average on a 10 point scale for the last 3 days/nights. Changes from baseline in SCORAD subjective assessments of itch were not evaluated. Only changes from baseline in SCORAD subjective assessments of sleep loss are presented below.

    Time frame: Baseline, Weeks 2, 4, 8 and 12

  20. Percent Change From Baseline in SCORAD Subjective VAS of Sleep Loss

    SCORAD is a validated scoring index for AD, which combines extent (A, 0-100), severity (B, 0-18), and subjective symptoms (C, 0-20) based on pruritus and sleep loss, each scored (0-10). The SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103). Subjective symptoms (ie, itch and sleep loss) are each scored by the participant using a VAS where "0" is no itch (or no sleep loss) and "10" is the worst imaginable itch (or sleep loss). The value for each should reflect the average on a 10 point scale for the last 3 days/nights. Changes from baseline in SCORAD subjective assessments of itch were not evaluated. Only changes from baseline in SCORAD subjective assessments of sleep loss are presented below.

    Time frame: Baseline, Weeks 2, 4, 8 and 12

  21. Number of Days When a Corticosteroid Not Used up to Day 88

    Time frame: Baseline to Day 88

  22. Change From Baseline in Children's Dermatology Life Quality Index (DLQI)

    The DLQI is a general dermatology questionnaire that consists of 10 items to assess participant-reported health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment).The DLQI is a psychometrically valid and reliable instrument that has been translated into several languages, and the DLQI total scores have been shown to be responsive to change. The minimally important difference for the DLQI has been estimated as a 3-5 point change from baseline. Each item is scored as "very much (3)", "a lot (2)", "a little (1)" and "not at all (0)". The score can range from 0 to 30. The higher values represent the worse dermatology life quality. Participants who withdrew from the study were counted as non-responder.

    Time frame: Baseline, Weeks 2, 4, 8 and 12

  23. Percentage of Participants With ≥2.5 Points at Baseline and Achieving ≥2.5 Points Improvement From Baseline in Children's DLQI

    The DLQI is a general dermatology questionnaire that consists of 10 items to assess participant-reported health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment).The DLQI is a psychometrically valid and reliable instrument that has been translated into several languages, and the DLQI total scores have been shown to be responsive to change. The minimally important difference for the DLQI has been estimated as a 3-5 point change from baseline. Each item is scored as "very much (3)", "a lot (2)", "a little (1)" and "not at all (0)". The score can range from 0 to 30. The higher values represent the worse dermatology life quality. Participants who withdrew from the study were counted as non-responder.

    Time frame: Baseline, Weeks 2, 4, 8 and 12

  24. Change From Baseline in Anxiety of Hospital Anxiety and Depression Scale (HADS)

    The HADS is a 14-item patient reported outcome (PRO) measure used to detect states of anxiety and depression over the past week. Seven of the items relate to anxiety and seven relate to depression. Each item is scored from 0 to 3 which means a person can score between 0 to 21 for either anxiety or depression. Higher values represent worse outcome.

    Time frame: Baseline, Weeks 2, 4, 8 and 12

  25. Change From Baseline in Depression of HADS

    The HADS is a 14-item patient reported outcome (PRO) measure used to detect states of anxiety and depression over the past week. Seven of the items relate to anxiety and seven relate to depression. Each item is scored from 0 to 3 which means a person can score between 0 to 21 for either anxiety or depression. Higher values represent worse outcome.

    Time frame: Baseline, Weeks 2, 4, 8 and 12

  26. Change From Baseline in Patient-Oriented Eczema Measure (POEM)

    The POEM is a 7-item PRO measure used to assess the impact of AD over the past week. Each item is scored as "no days (0)", "1-2 days (1)", "3-4 days (2)", "5-6 days (3)" and "every day (4)". The score ranges from 0 to 28. The higher values represent more severe AD.

    Time frame: Baseline, Weeks 2, 4, 8 and 12

  27. Change From Baseline in Dermatitis Family Impact (DFI) at Week 12

    The DFI is a validated 10-item measure filled out by the parent/caregiver of the patient used to assess the impact of the patient's eczema on the family. The instrument has a recall period of 7 days. Each item is scored as "very much (3)", "a lot (2)", "a little (1)" or "not at all (0)". The score can range from 0 to 30. The higher values represent the worse impact.

    Time frame: Baseline to Week 12

  28. Change From Baseline in Patient Global Assessment (PtGA)

    The PtGA asked the participant to evaluate the overall cutaneous disease at that point in time on a single-item, 5-point scale. The same category labels used in the IGA were used for the PtGA, ie, "severe (4)", "moderate (3)", "mild (2)","almost clear (1)", and "clear (0)". The PtGA was completed as per schedule of activities.

    Time frame: Baseline, Weeks 2, 4, 8 and 12

  29. Percentage of Participants With ≥2 Points at Baseline and Achieving 'Clear' or 'Almost Clear' and ≥2 Points Improvement From Baseline in PtGA

    The PtGA asked the participant to evaluate the overall cutaneous disease at that point in time on a single-item, 5-point scale. The same category labels used in the IGA were used for the PtGA, ie, "severe (4)", "moderate (3)", "mild (2)","almost clear (1)", and "clear (0)". The PtGA was completed as per schedule of activities.

    Time frame: Baseline, Weeks 2, 4, 8 and 12

  30. Change From Baseline in EuroQol Quality of Life 5-Dimension Youth Scale (EQ-5D-Y) VAS Score

    The EQ-5D is a validated, standardized, generic instrument that is the most widely used preference based health related quality of life questionnaire in cost effectiveness and health technologies assessment. The EQ-5D-Y is a version of the instrument specifically developed and validated for use by youths aged 12 through 17 years. Components assess level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, anxiety and depression. Score scale for each domain ranges from 1 (minimum) to 3 (maximum), with higher scores indicating worse health condition. In addition, respondents use a vertical, graduated Visual Analogue Scale (VAS) to rate their own health between 0 (the worst) and 100 (the best health state he/she can imagine).

    Time frame: Baseline, Weeks 2, 4, 8 and 12

  31. Change From Baseline in Pediatric Functional Assessment of Chronic Illness Therapy Fatigue Scale (Peds-FACIT-F) at Week 12

    The Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT-F) is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (none of the time) to 4 (all of the time). Larger the participant's response to the questions (with the exception of 2 negatively stated), greater was the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-F score for a total possible score of 0 (worse score) to 52 (better score), with higher scores representing better overall health status (less fatigue). Changes from baseline at Week 12 are presented below. Changes from baseline at other scheduled time points were not evaluated.

    Time frame: Baseline to Week 12

  32. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. TEAEs were AEs that occurred following the start of treatment or AEs increasing in severity during treatment. Treatment-related TEAEs were determined by the investigator.

    Time frame: 16 weeks

  33. Number of Participants With Serious Adverse Events (SAEs)

    A serious adverse event (SAE) was any untoward medical occurrence at any dose that resulted in death; was life threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect. Treatment-related SAEs were determined by the investigator.

    Time frame: 16 weeks

  34. Number of Participants Who Discontinued From the Study Due to TEAEs

    An AE was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. TEAEs were AEs that occurred following the start of treatment or AEs increasing in severity during treatment. Treatment-related TEAEs were determined by the investigator.

    Time frame: 16 weeks

  35. Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)

    Laboratory tests included hematology (including coagulation panel), clinical chemistry, lipid profile panel, and routine urinalysis. LLN is lower limit of normal. ULN is upper limit of normal.

    Time frame: 16 weeks

  36. Number of Participants With Electrocardiogram (ECG) Data Meeting Prespecified Criteria

    A 12-lead ECG was obtained using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and corrected QT intervals. All scheduled ECGs were performed after the participant had rested quietly for at least 10 minutes in a supine position. Reading of ECGs were performed by a central reader who has expertise reading and interpreting ECGs in adolescents. The QTcF interval is the only prespecified ECG criteria (Marked prolongation of the QTcF interval to \>500 ms or \>60 ms change from screening ECG); data are presented below.

    Time frame: 16 weeks

  37. Categorization of Vital Signs Data Meeting Prespecified Criteria

    Vital signs (pulse rate, systolic and diastolic blood pressure) were obtained with participant in the seated position, after having sat calmly for at least 5 minutes.

    Time frame: 16 weeks

  38. Fold Increase of Immunoglobulin G (IgG) Concentrations Against Specific Vaccine Antigens at 4 Weeks Post-Vaccination

    The immunogenicity analysis was to evaluate the effect of abrocitinib on immunogenicity to a tetanus, diphtheria and pertussis combination vaccine (Tdap) vaccine in adolescent participants 12 to \<18 years of age with moderate to severe AD. Participants who completed 8 weeks of treatment with study intervention received Tdap at Week 8, and had blood samples collected for the evaluation of immunogenicity to the vaccine at Weeks 8 and 12. The fold increase was defined as the ratio (post-vaccination: pre-vaccination) of concentration values. The geometric mean fold rise (GMFR) is presented below, and was calculated by first arithmetically averaging the logarithmically transformed ratio (post-vaccination: pre-vaccination) values, and then back transformation. A 95% CI for GMFR was constructed by back transformation of the CI for the logarithmically transformed GMFRs computed using the Student's t distribution.

    Time frame: 4 weeks post-vaccination with Tdap (Week 12)

  39. Plasma PF-04965842 Concentration at Week 8

    Time frame: 2 hours pre-dose at Week 8

  40. Plasma PF-04965842 Concentration at Week 12

    Time frame: 2 hours post-dose at Week 12

07

Results

Posted Jun 4, 2021

Participant flow

Participant flow — Overall Study
MilestonePlaceboPF-04965842 100mg QDPF-04965842 200mg QD
Started969594
Completed909291
Not completed633
Withdrew: Adverse event212
Withdrew: Lost to follow-up210
Withdrew: Protocol violation001
Withdrew: Withdrawal by subject110
Withdrew: Participant did not complete week 16 due to covid-19 impact100

Outcome measures

PrimaryPercentage of Participants Achieving Investigator's Global Assessment (IGA) Response of 'Clear' (0) or 'Almost Clear' (1) and ≥2 Points Improvement From Baseline at Week 12

The IGA of Atopic Dermatitis (AD) was scored on a 5-point scale (0-4), reflecting a global consideration of the erythema, induration and scaling. The overall severity of AD was assessed according to the 5-point scale: 0=Clear, 1=Almost Clear, 2=Mild, 3=Moderate, and 4=Severe. Participants who withdrew from the study were counted as non-responder.

Time frame:
Baseline to Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of 'Clear' (0) or 'Almost Clear' (1) and ≥2 Points Improvement From Baseline at Week 12
Percentage of participantsPlaceboPF-04965842 100mg QDPF-04965842 200mg QD
Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of 'Clear' (0) or 'Almost Clear' (1) and ≥2 Points Improvement From Baseline at Week 1224.5 (15.8 to 33.2)41.6 (31.3 to 51.8)46.2 (36.1 to 56.4)
Statistical analysis
  • Placebo vs PF-04965842 100mg QD · Cochran-Mantel-Haenszel · p = 0.0147 · Estimate of difference: 16.7 · 95% CI 3.5 to 29.9Estimate of the difference in percentages of response at Week 12 was calculated by PF-04965842 100 mg minus placebo
  • Placebo vs PF-04965842 200mg QD · Cochran-Mantel-Haenszel · p = 0.0030 · Estimate of difference: 20.6 · 95% CI 7.3 to 33.9Estimate of the difference in percentages of response at Week 12 was calculated by PF-04965842 200 mg minus placebo
PrimaryPercentage of Participants Achieving Eczema Area and Severity Index (EASI) Response ≥ 75% Improvement From Baseline at Week 12

The EASI quantifies the severity of AD based on both severity of lesion clinical signs and the percent of body surface area (BSA) affected. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD. Participants who withdrew from the study were counted as non-responder.

Time frame:
Baseline to Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Eczema Area and Severity Index (EASI) Response ≥ 75% Improvement From Baseline at Week 12
Percentage of participantsPlaceboPF-04965842 100mg QDPF-04965842 200mg QD
Percentage of Participants Achieving Eczema Area and Severity Index (EASI) Response ≥ 75% Improvement From Baseline at Week 1241.5 (31.5 to 51.4)68.5 (58.9 to 78.2)72.0 (62.9 to 81.2)
Statistical analysis
  • Placebo vs PF-04965842 100mg QD · Cochran-Mantel-Haenszel · p = 0.0002 · Estimate of difference: 26.5 · 95% CI 13.1 to 39.8Estimate of the difference in percentages of response at Week 12 was calculated by PF-04965842 100 mg minus placebo
  • Placebo vs PF-04965842 200mg QD · Cochran-Mantel-Haenszel · p = <0.0001 · Estimate of difference: 29.4 · 95% CI 16.3 to 42.5Estimate of the difference in percentages of response at Week 12 was calculated by PF-04965842 200 mg minus placebo
SecondaryPercentage of Participants Achieving ≥4 Points Improvement From Baseline in Peak Pruritis Numeric Rating Scale (PP-NRS) for Severity of Pruritus at Weeks 2, 4 and 12

PP-NRS assesses the severity of itch (pruritus) due to AD. Participants were asked to assess their worst itching due to AD on an NRS anchored by the terms "no itch" (0) and "worst itch imaginable" (10). Participants who withdrew from the study were counted as non-responder.

Time frame:
Baseline, Weeks 2, 4 and 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving ≥4 Points Improvement From Baseline in Peak Pruritis Numeric Rating Scale (PP-NRS) for Severity of Pruritus at Weeks 2, 4 and 12
Percentage of participantsPlaceboPF-04965842 100mg QDPF-04965842 200mg QD
Week 212.6 (6.0 to 19.3)27.2 (18.1 to 36.3)38.6 (28.5 to 48.8)
Week 420.7 (12.4 to 28.9)31.5 (21.8 to 41.1)50.0 (39.3 to 60.7)
Week 1229.8 (20.0 to 39.5)52.6 (41.4 to 63.9)55.4 (44.1 to 66.7)
Statistical analysis
  • Placebo vs PF-04965842 100mg QD · Cochran-Mantel-Haenszel · p = 0.0119 · Estimate of difference: 14.7 · 95% CI 3.5 to 25.9Estimate of the difference in percentages of response at Week 2 was calculated by PF-04965842 100 mg minus placebo
  • Placebo vs PF-04965842 200mg QD · Cochran-Mantel-Haenszel · p = <0.0001 · Estimate of difference: 26.1 · 95% CI 13.9 to 38.3Estimate of the difference in percentages of response at Week 2 was calculated by PF-04965842 200 mg minus placebo
  • Placebo vs PF-04965842 100mg QD · Cochran-Mantel-Haenszel · p = 0.0971 · Estimate of difference: 10.9 · 95% CI -1.8 to 23.6Estimate of the difference in percentages of response at Week 4 was calculated by PF-04965842 100 mg minus placebo
  • Placebo vs PF-04965842 200mg QD · Cochran-Mantel-Haenszel · p = <0.0001 · Estimate of difference: 29.4 · 95% CI 16.0 to 42.9Estimate of the difference in percentages of response at Week 4 was calculated by PF-04965842 200 mg minus placebo
  • Placebo vs PF-04965842 100mg QD · Cochran-Mantel-Haenszel · p = 0.0035 · Estimate of difference: 22.8 · 95% CI 8.0 to 37.7Estimate of the difference in percentages of response at Week 12 was calculated by PF-04965842 100 mg minus placebo
  • Placebo vs PF-04965842 200mg QD · Cochran-Mantel-Haenszel · p = 0.0013 · Estimate of difference: 25.6 · 95% CI 10.6 to 40.6Estimate of the difference in percentages of response at Week 12 was calculated by PF-04965842 200 mg minus placebo
SecondaryChange From Baseline in Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) at Week 12

The PSAAD is a daily patient reported symptom diary presented as a 15 item questionnaire that includes 11 items developed to measure symptoms of AD, along with 4 additional items for exploratory and psychometric validation purposes (Sleep \& Usual Activities Questions and Patient Global Impression of Severity \& Patient Global Impression of Change Questions). Participants answer each question about skin condition based on a 24 hour recall. Each question was evaluated on a 11-point scale ranging from 0 to 10, where higher scores indicate more impact on skin condition.The PSAAD total score is calculated as the average of the responses to each of the 11 items and ranges from 0 (none) to 10 (extreme), where higher scores indicate worse severity of AD symptoms.

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) at Week 12
Units on a scalePlaceboPF-04965842 100mg QDPF-04965842 200mg QD
Change From Baseline in Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) at Week 12-2.0 (-2.4 to -1.6)-2.5 (-2.9 to -2.1)-2.7 (-3.1 to -2.3)
Statistical analysis
  • Placebo vs PF-04965842 100mg QD · Mixed Models Analysis · p = 0.0664 · Mean difference (net): -0.5 · 95% CI -1.1 to 0.0The least squares mean difference at Week 12 was calculated by PF-04965842 100 mg minus placebo
  • Placebo vs PF-04965842 200mg QD · Mixed Models Analysis · p = 0.0142 · Mean difference (net): -0.7 · 95% CI -1.3 to -0.1The least squares mean difference at Week 12 was calculated by PF-04965842 200 mg minus placebo
SecondaryPercentage of Participants Achieving IGA Response of 'Clear' or 'Almost Clear' and ≥2 Points Improvement From Baseline at All Scheduled Time Points Except Week 12

The IGA of AD is scored on a 5-point scale (0-4), reflecting a global consideration of the erythema, induration and scaling. The overall severity of AD was assessed according to the 5-point scale: 0=Clear, 1=Almost Clear, 2=Mild, 3=Moderate, and 4=Severe. Participants who withdrew from the study were counted as non-responder.

Time frame:
Baseline, Weeks 2, 4 and 8
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving IGA Response of 'Clear' or 'Almost Clear' and ≥2 Points Improvement From Baseline at All Scheduled Time Points Except Week 12
Percentage of participantsPlaceboPF-04965842 100mg QDPF-04965842 200mg QD
Week 21.1 (0.0 to 3.2)6.5 (1.5 to 11.6)12.8 (6.0 to 19.5)
Week 43.1 (0.0 to 6.6)19.6 (11.5 to 27.7)38.3 (28.5 to 48.1)
Week 816.0 (8.6 to 23.4)30.8 (21.3 to 40.3)48.9 (38.7 to 59.1)
SecondaryPercentage of Participants Achieving EASI Response ≥ 75% Improvement From Baseline at All Scheduled Time Points Except Week 12

The EASI quantifies the severity of AD based on both severity of lesion clinical signs and the percent of BSA affected. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD. Participants who withdrew from the study were counted as non-responder.

Time frame:
Baseline, Weeks 2, 4 and 8
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving EASI Response ≥ 75% Improvement From Baseline at All Scheduled Time Points Except Week 12
Percentage of participantsPlaceboPF-04965842 100mg QDPF-04965842 200mg QD
Week 24.4 (0.2 to 8.6)19.6 (11.5 to 27.7)25.5 (16.7 to 34.3)
Week 414.6 (7.5 to 21.6)41.3 (31.2 to 51.4)63.8 (54.1 to 73.5)
Week 833.3 (23.8 to 42.9)60.4 (50.4 to 70.5)68.5 (59.0 to 78.0)
SecondaryPercentage of Participants Achieving EASI Response ≥ 50% Improvement From Baseline

The EASI quantifies the severity of AD based on both severity of lesion clinical signs and the percent of BSA affected. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD. Participants who withdrew from the study were counted as non-responder.

Time frame:
Baseline, Weeks 2, 4, 8 and 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving EASI Response ≥ 50% Improvement From Baseline
Percentage of participantsPlaceboPF-04965842 100mg QDPF-04965842 200mg QD
Week 224.2 (15.4 to 33.0)55.4 (45.3 to 65.6)64.9 (55.2 to 74.5)
Week 451.0 (41.0 to 61.0)75.0 (66.2 to 83.8)81.9 (74.1 to 89.7)
Week 865.6 (55.9 to 75.2)85.7 (78.5 to 92.9)82.6 (74.9 to 90.4)
Week 1269.1 (59.8 to 78.5)87.6 (80.8 to 94.5)87.1 (80.3 to 93.9)
SecondaryPercentage of Participants Achieving EASI Response ≥ 90% Improvement From Baseline

The EASI quantifies the severity of AD based on both severity of lesion clinical signs and the percent of BSA affected. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD. Participants who withdrew from the study were counted as non-responder.

Time frame:
Baseline, Weeks 2, 4, 8 and 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving EASI Response ≥ 90% Improvement From Baseline
Percentage of participantsPlaceboPF-04965842 100mg QDPF-04965842 200mg QD
Week 20 (0.0 to 4.0)8.7 (2.9 to 14.5)10.6 (4.4 to 16.9)
Week 42.1 (0.0 to 4.9)17.4 (9.6 to 25.1)30.9 (21.5 to 40.2)
Week 814.0 (6.9 to 21.0)29.7 (20.3 to 39.1)40.2 (30.2 to 50.2)
Week 1218.1 (10.3 to 25.9)41.6 (31.3 to 51.8)49.5 (39.3 to 59.6)
SecondaryPercentage of Participants Achieving EASI Response =100% Improvement From Baseline

The EASI quantifies the severity of AD based on both severity of lesion clinical signs and the percent of BSA affected. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD. Participants who withdrew from the study were counted as non-responder.

Time frame:
Baseline, Weeks 2, 4, 8 and 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving EASI Response =100% Improvement From Baseline
Percentage of participantsPlaceboPF-04965842 100mg QDPF-04965842 200mg QD
Week 20 (0.0 to 4.0)1.1 (0.0 to 3.2)0 (0.0 to 3.8)
Week 40 (0.0 to 3.8)2.2 (0.0 to 5.2)5.3 (0.8 to 9.9)
Week 80 (0.0 to 3.9)3.3 (0.0 to 7.0)9.8 (3.7 to 15.9)
Week 122.1 (0.0 to 5.0)2.2 (0.0 to 5.3)8.6 (2.9 to 14.3)
SecondaryPercent Change From Baseline in EASI Score

The EASI quantifies the severity of AD based on both severity of lesion clinical signs and the percent of BSA affected. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of AD. Participants who withdrew from the study were counted as non-responder.

Time frame:
Baseline, Weeks 2, 4, 8 and 12
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in EASI Score
Percent changePlaceboPF-04965842 100mg QDPF-04965842 200mg QD
Week 2-27.6 (-34.0 to -21.2)-51.5 (-57.9 to -45.1)-54.5 (-61.0 to -48.0)
Week 4-41.7 (-48.3 to -35.1)-66.1 (-72.7 to -59.4)-74.3 (-81.0 to -67.5)
Week 8-57.6 (-63.4 to -51.8)-72.6 (-78.4 to -66.8)-77.8 (-83.7 to -71.9)
Week 12-63.7 (-69.5 to -57.9)-77.3 (-83.1 to -71.5)-80.6 (-86.5 to -74.8)
SecondaryPercentage of Participants Achieving ≥4 Points Improvement From Baseline in PP-NRS for Severity of Pruritus at All Scheduled Time Points Other Than Weeks 2, 4 and 12

PP-NRS assesses the severity of itch (pruritus) due to AD. Participants were asked to assess their worst itching due to AD on an NRS anchored by the terms "no itch" (0) and "worst itch imaginable" (10). Participants who withdrew from the study were counted as non-responder.

Time frame:
Baseline, Days 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving ≥4 Points Improvement From Baseline in PP-NRS for Severity of Pruritus at All Scheduled Time Points Other Than Weeks 2, 4 and 12
Percentage of participantsPlaceboPF-04965842 100mg QDPF-04965842 200mg QD
Day 21.2 (0.0 to 3.6)2.8 (0.0 to 6.7)3.9 (0.0 to 8.2)
Day 30 (0.0 to 4.6)5.1 (0.2 to 9.9)7.7 (1.8 to 13.6)
Day 44.9 (0.2 to 9.7)11.5 (4.4 to 18.6)14.3 (6.5 to 22.1)
Day 56.9 (1.1 to 12.8)12.2 (5.1 to 19.3)18.5 (10.1 to 27.0)
Day 68.8 (2.6 to 14.9)16.0 (8.1 to 24.0)21.3 (12.3 to 30.2)
Day 710.1 (3.5 to 16.8)16.0 (8.1 to 24.0)21.3 (12.3 to 30.2)
Day 84.0 (0.0 to 8.4)17.3 (8.8 to 25.9)25.0 (15.3 to 34.7)
Day 96.0 (0.9 to 11.1)16.0 (7.7 to 24.3)25.0 (15.5 to 34.5)
Day 108.3 (2.4 to 14.2)15.6 (7.5 to 23.7)28.8 (18.8 to 38.7)
Day 117.6 (1.8 to 13.4)20.8 (11.7 to 29.8)27.0 (16.9 to 37.1)
Day 1210.8 (3.7 to 17.9)22.2 (12.6 to 31.8)23.6 (13.8 to 33.4)
Day 1310.0 (3.4 to 16.6)26.3 (16.6 to 35.9)31.2 (20.8 to 41.5)
Day 149.5 (3.2 to 15.8)24.7 (15.3 to 34.1)32.4 (21.8 to 43.1)
Day 1514.3 (6.8 to 21.8)27.7 (18.1 to 37.3)37.8 (27.3 to 48.3)
SecondaryTime to First Achieve ≥4 Points Improvement From Baseline in PP-NRS for Severity of Pruritus

PP-NRS assesses the severity of itch (pruritus) due to AD. Participants were asked to assess their worst itching due to AD on an NRS anchored by the terms "no itch" (0) and "worst itch imaginable" (10).

Time frame:
Baseline to Week 16
Reported as:
Median · Days
Time to First Achieve ≥4 Points Improvement From Baseline in PP-NRS for Severity of Pruritus
DaysPlaceboPF-04965842 100mg QDPF-04965842 200mg QD
Time to First Achieve ≥4 Points Improvement From Baseline in PP-NRS for Severity of Pruritus90.0 (62.0 to NA)70.0 (30.0 to 85.0)29.0 (15.0 to 61.0)
SecondaryPercent Change From Baseline in PP-NRS for Severity of Pruritus

PP-NRS assesses the severity of itch (pruritus) due to AD. Participants were asked to assess their worst itching due to AD on an NRS anchored by the terms "no itch" (0) and "worst itch imaginable" (10).

Time frame:
Baseline, Days 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in PP-NRS for Severity of Pruritus
Percent changePlaceboPF-04965842 100mg QDPF-04965842 200mg QD
Day 2-0.9 (-5.5 to 3.6)-9.5 (-14.2 to -4.8)-5.4 (-10.0 to -0.7)
Day 3-1.1 (-6.0 to 3.8)-11.3 (-16.2 to -6.4)-10.2 (-15.2 to -5.2)
Day 4-5.0 (-10.6 to 0.5)-14.6 (-20.2 to -9.1)-14.7 (-20.3 to -9.1)
Day 5-9.5 (-15.8 to -3.2)-16.1 (-22.3 to -9.9)-17.6 (-23.9 to -11.3)
Day 6-8.7 (-15.2 to -2.2)-18.5 (-25.0 to -12.1)-18.7 (-25.3 to -12.1)
Day 7-12.3 (-19.4 to -5.2)-20.0 (-27.1 to -12.9)-18.8 (-26.0 to -11.6)
Day 8-10.6 (-17.9 to -3.3)-21.6 (-28.9 to -14.2)-22.7 (-30.2 to -15.3)
Day 9-9.9 (-17.6 to -2.3)-20.9 (-28.7 to -13.2)-21.7 (-29.5 to -13.9)
Day 10-10.8 (-17.8 to -3.8)-26.1 (-33.1 to -19.0)-28.0 (-35.1 to -20.8)
Day 11-10.7 (-17.7 to -3.7)-26.5 (-33.5 to -19.4)-26.3 (-33.5 to -19.1)
Day 12-11.0 (-18.0 to -4.0)-27.0 (-34.0 to -20.0)-28.9 (-36.1 to -21.8)
Day 13-14.1 (-20.4 to -7.8)-25.2 (-31.5 to -18.8)-32.5 (-39.0 to -26.0)
Day 14-12.0 (-18.1 to -5.8)-29.4 (-35.5 to -23.2)-35.3 (-41.6 to -29.0)
Day 15-15.8 (-22.7 to -8.8)-30.7 (-37.7 to -23.7)-33.4 (-40.5 to -26.3)
SecondaryChange From Baseline in Percentage Body Surface Area (BSA)

BSA efficacy is derived from the sum of the BSA in handprints across 4 body regions assessed as part of the EASI assessment. Handprint refers to that of each individual participant for their own measurement. The BSA efficacy ranges from 0 to 100%, with higher values representing greater severity of AD. The percentage BSA ranges from 0 to 100, with higher scores representing greater severity of AD. Since the scalp, palms, and soles were excluded from the BSA (efficacy) assessment, the maximum possible percentage BSA was less than 100.

Time frame:
Baseline, Weeks 2, 4, 8 and 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Percentage Body Surface Area (BSA)
Units on a scalePlaceboPF-04965842 100mg QDPF-04965842 200mg QD
Week 2-10.9 (-14.0 to -7.8)-21.0 (-24.1 to -17.9)-20.7 (-23.8 to -17.6)
Week 4-15.1 (-18.4 to -11.7)-27.7 (-31.0 to -24.3)-32.6 (-36.0 to -29.1)
Week 8-21.8 (-25.3 to -18.3)-32.6 (-36.1 to -29.1)-34.1 (-37.7 to -30.6)
Week 12-24.2 (-27.8 to -20.7)-34.4 (-38.0 to -30.8)-35.2 (-38.8 to -31.6)
SecondaryPercent Change From Baseline in Percentage BSA

BSA efficacy is derived from the sum of the BSA in handprints across 4 body regions assessed as part of the EASI assessment. Handprint refers to that of each individual participant for their own measurement. The BSA efficacy ranges from 0 to 100%, with higher values representing greater severity of AD. The percentage BSA ranges from 0 to 100, with higher scores representing greater severity of AD. Since the scalp, palms, and soles were excluded from the BSA (efficacy) assessment, the maximum possible percentage BSA was less than 100.

Time frame:
Baseline, Weeks 2, 4, 8 and 12
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Percentage BSA
Percent changePlaceboPF-04965842 100mg QDPF-04965842 200mg QD
Week 2-20.6 (-26.7 to -14.5)-40.4 (-46.5 to -34.3)-42.2 (-48.3 to -36.1)
Week 4-29.0 (-36.3 to -21.8)-55.4 (-62.7 to -48.1)-66.0 (-73.4 to -58.6)
Week 8-46.0 (-52.6 to -39.3)-65.7 (-72.4 to -59.1)-69.5 (-76.3 to -62.8)
Week 12-53.4 (-60.1 to -46.7)-71.4 (-78.2 to -64.7)-72.6 (-79.3 to -65.8)
SecondaryPercentage of Participants Achieving Percentage BSA < 5% at Week 12

BSA efficacy is derived from the sum of the BSA in handprints across 4 body regions assessed as part of the EASI assessment. Handprint refers to that of each individual participant for their own measurement. The BSA efficacy ranges from 0 to 100%, with higher values representing greater severity of AD. The percentage BSA ranges from 0 to 100, with higher scores representing greater severity of AD. Since the scalp, palms, and soles were excluded from the BSA (efficacy) assessment, the maximum possible percentage BSA was less than 100.

Time frame:
Baseline to Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Percentage BSA < 5% at Week 12
Percentage of participantsPlaceboPF-04965842 100mg QDPF-04965842 200mg QD
Percentage of Participants Achieving Percentage BSA < 5% at Week 1224.5 (15.8 to 33.2)38.2 (28.1 to 48.3)36.6 (26.8 to 46.3)
SecondaryPercentage of Participants Achieving Scoring Atopic Dermatitis (SCORAD) Response ≥ 50% Improvement From Baseline

SCORAD is a validated scoring index for AD,which combines extent (0-100),severity (0-18),and subjective symptoms (0-20) based on pruritus and sleep loss,each scored (0-10). Extent,denoted as A,is measured by BSA affected by AD as a percentage of the whole BSA.The score for each body region is added up to determine A (maximum of 100).Severity, denoted as B,consists of the severity of several signs.Each is assessed as none(0),mild(1),moderate(2) or severe(3).The severity scores are added together to give B (maximum of 18).Subjective symptoms,denoted as C,are each scored by the participant using a NRS where "0" is no itch (or no sleeplessness) and "10" is the worst imaginable itch (or sleeplessness).These scores are added to give 'C' (maximum of 20).SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103).Higher values of SCORAD represent worse outcome.

Time frame:
Baseline, Weeks 2, 4, 8 and 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Scoring Atopic Dermatitis (SCORAD) Response ≥ 50% Improvement From Baseline
Percentage of participantsPlaceboPF-04965842 100mg QDPF-04965842 200mg QD
Week 28.6 (2.9 to 14.3)22.6 (14.1 to 31.1)29.0 (19.8 to 38.3)
Week 424.0 (15.4 to 32.5)44.1 (34.0 to 54.2)64.1 (54.3 to 73.9)
Week 834.0 (24.5 to 43.6)65.6 (55.9 to 75.2)75.0 (66.2 to 83.8)
Week 1237.6 (27.8 to 47.5)75.6 (66.7 to 84.4)73.9 (64.9 to 82.9)
SecondaryPercentage of Participants Achieving SCORAD Response ≥ 75% Improvement From Baseline

SCORAD is a validated scoring index for AD,which combines extent (0-100),severity (0-18),and subjective symptoms (0-20) based on pruritus and sleep loss,each scored (0-10). Extent,denoted as A,is measured by BSA affected by AD as a percentage of the whole BSA.The score for each body region is added up to determine A (maximum of 100).Severity, denoted as B,consists of the severity of several signs.Each is assessed as none(0),mild(1),moderate(2) or severe(3).The severity scores are added together to give B (maximum of 18).Subjective symptoms,denoted as C,are each scored by the participant using a NRS where "0" is no itch (or no sleeplessness) and "10" is the worst imaginable itch (or sleeplessness).These scores are added to give 'C' (maximum of 20).SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103).Higher values of SCORAD represent worse outcome.

Time frame:
Baseline, Weeks 2, 4, 8 and 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving SCORAD Response ≥ 75% Improvement From Baseline
Percentage of participantsPlaceboPF-04965842 100mg QDPF-04965842 200mg QD
Week 20 (0.0 to 3.9)5.4 (0.8 to 10.0)7.5 (2.2 to 12.9)
Week 40 (0.0 to 3.8)11.8 (5.3 to 18.4)21.7 (13.3 to 30.2)
Week 88.5 (2.9 to 14.2)17.2 (9.5 to 24.9)33.7 (24.0 to 43.4)
Week 1212.9 (6.1 to 19.7)36.7 (26.7 to 46.6)34.8 (25.1 to 44.5)
SecondaryChange From Baseline in SCORAD Total Score

SCORAD is a validated scoring index for AD,which combines extent (0-100),severity (0-18),and subjective symptoms (0-20) based on pruritus and sleep loss,each scored (0-10). Extent,denoted as A,is measured by BSA affected by AD as a percentage of the whole BSA.The score for each body region is added up to determine A (maximum of 100).Severity, denoted as B,consists of the severity of several signs.Each is assessed as none(0),mild(1),moderate(2) or severe(3).The severity scores are added together to give B (maximum of 18).Subjective symptoms,denoted as C,are each scored by the participant using a NRS where "0" is no itch (or no sleeplessness) and "10" is the worst imaginable itch (or sleeplessness).These scores are added to give 'C' (maximum of 20).SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103).Higher values of SCORAD represent worse outcome.

Time frame:
Baseline, Weeks 2, 4, 8 and 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in SCORAD Total Score
Units on a scalePlaceboPF-04965842 100mg QDPF-04965842 200mg QD
Week 2-12.3 (-15.4 to -9.2)-24.6 (-27.7 to -21.6)-25.8 (-28.9 to -22.7)
Week 4-20.2 (-23.3 to -17.0)-32.4 (-35.5 to -29.2)-38.0 (-41.2 to -34.8)
Week 8-26.6 (-30.0 to -23.2)-37.3 (-40.7 to -33.9)-41.5 (-45.0 to -38.0)
Week 12-30.2 (-33.9 to -26.4)-40.9 (-44.7 to -37.2)-42.9 (-46.7 to -39.1)
SecondaryPercent Change From Baseline in SCORAD Total Score

SCORAD is a validated scoring index for AD,which combines extent (0-100),severity (0-18),and subjective symptoms (0-20) based on pruritus and sleep loss,each scored (0-10). Extent,denoted as A,is measured by BSA affected by AD as a percentage of the whole BSA.The score for each body region is added up to determine A (maximum of 100).Severity, denoted as B,consists of the severity of several signs.Each is assessed as none(0),mild(1),moderate(2) or severe(3).The severity scores are added together to give B (maximum of 18).Subjective symptoms,denoted as C,are each scored by the participant using a NRS where "0" is no itch (or no sleeplessness) and "10" is the worst imaginable itch (or sleeplessness).These scores are added to give 'C' (maximum of 20).SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103).Higher values of SCORAD represent worse outcome.

Time frame:
Baseline, Weeks 2, 4, 8 and 12
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in SCORAD Total Score
Percent changePlaceboPF-04965842 100mg QDPF-04965842 200mg QD
Week 2-18.7 (-23.1 to -14.2)-36.1 (-40.6 to -31.7)-38.7 (-43.2 to -34.2)
Week 4-30.0 (-34.5 to -25.5)-47.4 (-52.0 to -42.9)-56.9 (-61.6 to -52.3)
Week 8-39.9 (-44.9 to -34.8)-54.0 (-59.0 to -48.9)-62.0 (-67.2 to -56.9)
Week 12-44.4 (-50.1 to -38.8)-59.2 (-64.9 to -53.6)-64.3 (-70.1 to -58.6)
SecondaryChange From Baseline in SCORAD Subjective Visual Analogue Scale (VAS) of Sleep Loss

SCORAD is a validated scoring index for AD, which combines extent (A, 0-100), severity (B, 0-18), and subjective symptoms (C, 0-20) based on pruritus and sleep loss, each scored (0-10). The SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103). Subjective symptoms (ie, itch and sleep loss) are each scored by the participant using a VAS where "0" is no itch (or no sleep loss) and "10" is the worst imaginable itch (or sleep loss). The value for each should reflect the average on a 10 point scale for the last 3 days/nights. Changes from baseline in SCORAD subjective assessments of itch were not evaluated. Only changes from baseline in SCORAD subjective assessments of sleep loss are presented below.

Time frame:
Baseline, Weeks 2, 4, 8 and 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in SCORAD Subjective Visual Analogue Scale (VAS) of Sleep Loss
Units on a scalePlaceboPF-04965842 100mg QDPF-04965842 200mg QD
Week 2-0.9 (-1.4 to -0.4)-2.1 (-2.6 to -1.6)-2.6 (-3.1 to -2.1)
Week 4-1.8 (-2.3 to -1.3)-2.9 (-3.3 to -2.4)-3.4 (-3.9 to -2.9)
Week 8-2.2 (-2.7 to -1.7)-3.3 (-3.8 to -2.9)-3.7 (-4.2 to -3.2)
Week 12-2.7 (-3.2 to -2.2)-3.5 (-3.9 to -3.0)-3.9 (-4.4 to -3.4)
SecondaryPercent Change From Baseline in SCORAD Subjective VAS of Sleep Loss

SCORAD is a validated scoring index for AD, which combines extent (A, 0-100), severity (B, 0-18), and subjective symptoms (C, 0-20) based on pruritus and sleep loss, each scored (0-10). The SCORAD for an individual is calculated by the formula: A/5 + 7B/2 + C (can range from 0 to 103). Subjective symptoms (ie, itch and sleep loss) are each scored by the participant using a VAS where "0" is no itch (or no sleep loss) and "10" is the worst imaginable itch (or sleep loss). The value for each should reflect the average on a 10 point scale for the last 3 days/nights. Changes from baseline in SCORAD subjective assessments of itch were not evaluated. Only changes from baseline in SCORAD subjective assessments of sleep loss are presented below.

Time frame:
Baseline, Weeks 2, 4, 8 and 12
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in SCORAD Subjective VAS of Sleep Loss
Percent changePlaceboPF-04965842 100mg QDPF-04965842 200mg QD
Week 22.6 (-101.2 to 106.3)65.1 (-39.2 to 169.4)-36.5 (-140.7 to 67.8)
Week 4-20.0 (-35.2 to -4.9)-35.2 (-50.7 to -19.8)-53.4 (-69.1 to -37.8)
Week 8-24.7 (-60.1 to 10.8)-44.2 (-79.9 to -8.5)-30.6 (-66.7 to 5.5)
Week 12-39.5 (-77.7 to -1.3)-49.8 (-88.3 to -11.3)-35.2 (-74.1 to 3.7)
SecondaryNumber of Days When a Corticosteroid Not Used up to Day 88
Time frame:
Baseline to Day 88
Reported as:
Least squares mean · Days
Number of Days When a Corticosteroid Not Used up to Day 88
DaysPlaceboPF-04965842 100mg QDPF-04965842 200mg QD
Number of Days When a Corticosteroid Not Used up to Day 886.8 (2.0 to 11.6)10.9 (6.2 to 15.5)15.1 (10.2 to 19.9)
SecondaryChange From Baseline in Children's Dermatology Life Quality Index (DLQI)

The DLQI is a general dermatology questionnaire that consists of 10 items to assess participant-reported health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment).The DLQI is a psychometrically valid and reliable instrument that has been translated into several languages, and the DLQI total scores have been shown to be responsive to change. The minimally important difference for the DLQI has been estimated as a 3-5 point change from baseline. Each item is scored as "very much (3)", "a lot (2)", "a little (1)" and "not at all (0)". The score can range from 0 to 30. The higher values represent the worse dermatology life quality. Participants who withdrew from the study were counted as non-responder.

Time frame:
Baseline, Weeks 2, 4, 8 and 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Children's Dermatology Life Quality Index (DLQI)
Units on a scalePlaceboPF-04965842 100mg QDPF-04965842 200mg QD
Week 2-4.2 (-5.1 to -3.3)-6.1 (-7.1 to -5.2)-6.3 (-7.2 to -5.3)
Week 4-5.4 (-6.3 to -4.5)-7.3 (-8.2 to -6.4)-7.6 (-8.6 to -6.7)
Week 8-6.1 (-7.0 to -5.1)-8.1 (-9.1 to -7.1)-8.2 (-9.2 to -7.2)
Week 12-6.3 (-7.4 to -5.3)-8.6 (-9.6 to -7.5)-8.7 (-9.7 to -7.6)
SecondaryPercentage of Participants With ≥2.5 Points at Baseline and Achieving ≥2.5 Points Improvement From Baseline in Children's DLQI

The DLQI is a general dermatology questionnaire that consists of 10 items to assess participant-reported health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment).The DLQI is a psychometrically valid and reliable instrument that has been translated into several languages, and the DLQI total scores have been shown to be responsive to change. The minimally important difference for the DLQI has been estimated as a 3-5 point change from baseline. Each item is scored as "very much (3)", "a lot (2)", "a little (1)" and "not at all (0)". The score can range from 0 to 30. The higher values represent the worse dermatology life quality. Participants who withdrew from the study were counted as non-responder.

Time frame:
Baseline, Weeks 2, 4, 8 and 12
Reported as:
Number · Percentage of participants
Percentage of Participants With ≥2.5 Points at Baseline and Achieving ≥2.5 Points Improvement From Baseline in Children's DLQI
Percentage of participantsPlaceboPF-04965842 100mg QDPF-04965842 200mg QD
Week 261.5 (51.5 to 71.5)73.6 (64.6 to 82.7)71.3 (62.1 to 80.4)
Week 473.7 (64.8 to 82.5)82.4 (74.6 to 90.2)73.4 (64.5 to 82.3)
Week 871.0 (61.7 to 80.2)85.9 (78.8 to 93.0)79.6 (71.4 to 87.8)
Week 1267.7 (58.2 to 77.2)80.9 (72.7 to 89.1)78.5 (70.1 to 86.8)
SecondaryChange From Baseline in Anxiety of Hospital Anxiety and Depression Scale (HADS)

The HADS is a 14-item patient reported outcome (PRO) measure used to detect states of anxiety and depression over the past week. Seven of the items relate to anxiety and seven relate to depression. Each item is scored from 0 to 3 which means a person can score between 0 to 21 for either anxiety or depression. Higher values represent worse outcome.

Time frame:
Baseline, Weeks 2, 4, 8 and 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Anxiety of Hospital Anxiety and Depression Scale (HADS)
Units on a scalePlaceboPF-04965842 100mg QDPF-04965842 200mg QD
Week 2-1.2 (-1.7 to -0.7)-1.6 (-2.1 to -1.1)-1.3 (-1.8 to -0.8)
Week 4-1.5 (-2.1 to -1.0)-1.6 (-2.2 to -1.1)-1.9 (-2.5 to -1.3)
Week 8-1.7 (-2.3 to -1.1)-2.1 (-2.7 to -1.5)-2.2 (-2.8 to -1.5)
Week 12-2.1 (-2.7 to -1.5)-2.0 (-2.6 to -1.4)-2.4 (-3.0 to -1.8)
SecondaryChange From Baseline in Depression of HADS

The HADS is a 14-item patient reported outcome (PRO) measure used to detect states of anxiety and depression over the past week. Seven of the items relate to anxiety and seven relate to depression. Each item is scored from 0 to 3 which means a person can score between 0 to 21 for either anxiety or depression. Higher values represent worse outcome.

Time frame:
Baseline, Weeks 2, 4, 8 and 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Depression of HADS
Units on a scalePlaceboPF-04965842 100mg QDPF-04965842 200mg QD
Week 2-0.8 (-1.3 to -0.3)-1.2 (-1.7 to -0.8)-0.8 (-1.3 to -0.3)
Week 4-0.8 (-1.3 to -0.3)-1.3 (-1.8 to -0.8)-1.3 (-1.8 to -0.8)
Week 8-1.1 (-1.6 to -0.6)-1.4 (-1.9 to -0.9)-1.2 (-1.7 to -0.7)
Week 12-1.0 (-1.5 to -0.5)-1.4 (-1.9 to -0.8)-1.2 (-1.7 to -0.6)
SecondaryChange From Baseline in Patient-Oriented Eczema Measure (POEM)

The POEM is a 7-item PRO measure used to assess the impact of AD over the past week. Each item is scored as "no days (0)", "1-2 days (1)", "3-4 days (2)", "5-6 days (3)" and "every day (4)". The score ranges from 0 to 28. The higher values represent more severe AD.

Time frame:
Baseline, Weeks 2, 4, 8 and 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Patient-Oriented Eczema Measure (POEM)
Units on a scalePlaceboPF-04965842 100mg QDPF-04965842 200mg QD
Week 2-3.4 (-4.7 to -2.1)-6.9 (-8.2 to -5.6)-8.2 (-9.5 to -6.9)
Week 4-4.8 (-6.0 to -3.6)-9.5 (-10.7 to -8.3)-10.6 (-11.9 to -9.4)
Week 8-5.4 (-6.7 to -4.0)-10.0 (-11.4 to -8.7)-10.6 (-12.0 to -9.3)
Week 12-6.9 (-8.3 to -5.6)-11.1 (-12.5 to -9.7)-10.9 (-12.2 to -9.5)
SecondaryChange From Baseline in Dermatitis Family Impact (DFI) at Week 12

The DFI is a validated 10-item measure filled out by the parent/caregiver of the patient used to assess the impact of the patient's eczema on the family. The instrument has a recall period of 7 days. Each item is scored as "very much (3)", "a lot (2)", "a little (1)" or "not at all (0)". The score can range from 0 to 30. The higher values represent the worse impact.

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Dermatitis Family Impact (DFI) at Week 12
Units on a scalePlaceboPF-04965842 100mg QDPF-04965842 200mg QD
Change From Baseline in Dermatitis Family Impact (DFI) at Week 12-5.2 (-6.5 to -3.9)-6.7 (-7.9 to -5.4)-7.3 (-8.6 to -6.0)
SecondaryChange From Baseline in Patient Global Assessment (PtGA)

The PtGA asked the participant to evaluate the overall cutaneous disease at that point in time on a single-item, 5-point scale. The same category labels used in the IGA were used for the PtGA, ie, "severe (4)", "moderate (3)", "mild (2)","almost clear (1)", and "clear (0)". The PtGA was completed as per schedule of activities.

Time frame:
Baseline, Weeks 2, 4, 8 and 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Patient Global Assessment (PtGA)
Units on a scalePlaceboPF-04965842 100mg QDPF-04965842 200mg QD
Week 2-0.4 (-0.6 to -0.3)-0.7 (-0.9 to -0.6)-1.0 (-1.1 to -0.8)
Week 4-0.7 (-0.8 to -0.5)-0.9 (-1.1 to -0.8)-1.2 (-1.4 to -1.1)
Week 8-0.8 (-1.0 to -0.6)-1.2 (-1.3 to -1.0)-1.4 (-1.6 to -1.2)
Week 12-0.9 (-1.1 to -0.7)-1.4 (-1.6 to -1.2)-1.6 (-1.8 to -1.4)
SecondaryPercentage of Participants With ≥2 Points at Baseline and Achieving 'Clear' or 'Almost Clear' and ≥2 Points Improvement From Baseline in PtGA

The PtGA asked the participant to evaluate the overall cutaneous disease at that point in time on a single-item, 5-point scale. The same category labels used in the IGA were used for the PtGA, ie, "severe (4)", "moderate (3)", "mild (2)","almost clear (1)", and "clear (0)". The PtGA was completed as per schedule of activities.

Time frame:
Baseline, Weeks 2, 4, 8 and 12
Reported as:
Number · Percentage of participants
Percentage of Participants With ≥2 Points at Baseline and Achieving 'Clear' or 'Almost Clear' and ≥2 Points Improvement From Baseline in PtGA
Percentage of participantsPlaceboPF-04965842 100mg QDPF-04965842 200mg QD
Week 21.1 (0.0 to 3.2)5.4 (0.8 to 10.1)5.3 (0.8 to 9.9)
Week 44.2 (0.2 to 8.2)14.1 (7.0 to 21.2)20.2 (12.1 to 28.3)
Week 86.4 (1.4 to 11.3)22.6 (14.1 to 31.1)26.9 (17.9 to 35.9)
Week 1210.6 (4.4 to 16.9)30.0 (20.5 to 39.5)36.6 (26.8 to 46.3)
SecondaryChange From Baseline in EuroQol Quality of Life 5-Dimension Youth Scale (EQ-5D-Y) VAS Score

The EQ-5D is a validated, standardized, generic instrument that is the most widely used preference based health related quality of life questionnaire in cost effectiveness and health technologies assessment. The EQ-5D-Y is a version of the instrument specifically developed and validated for use by youths aged 12 through 17 years. Components assess level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, anxiety and depression. Score scale for each domain ranges from 1 (minimum) to 3 (maximum), with higher scores indicating worse health condition. In addition, respondents use a vertical, graduated Visual Analogue Scale (VAS) to rate their own health between 0 (the worst) and 100 (the best health state he/she can imagine).

Time frame:
Baseline, Weeks 2, 4, 8 and 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in EuroQol Quality of Life 5-Dimension Youth Scale (EQ-5D-Y) VAS Score
Units on a scalePlaceboPF-04965842 100mg QDPF-04965842 200mg QD
Week 27.140 (3.787 to 10.492)11.241 (7.882 to 14.601)12.141 (8.763 to 15.520)
Week 48.784 (5.625 to 11.943)13.222 (10.020 to 16.423)14.677 (11.438 to 17.917)
Week 88.415 (4.888 to 11.941)14.502 (10.977 to 18.028)14.653 (11.076 to 18.231)
Week 129.944 (6.373 to 13.515)14.226 (10.624 to 17.828)15.756 (12.153 to 19.360)
SecondaryChange From Baseline in Pediatric Functional Assessment of Chronic Illness Therapy Fatigue Scale (Peds-FACIT-F) at Week 12

The Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT-F) is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (none of the time) to 4 (all of the time). Larger the participant's response to the questions (with the exception of 2 negatively stated), greater was the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-F score for a total possible score of 0 (worse score) to 52 (better score), with higher scores representing better overall health status (less fatigue). Changes from baseline at Week 12 are presented below. Changes from baseline at other scheduled time points were not evaluated.

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Pediatric Functional Assessment of Chronic Illness Therapy Fatigue Scale (Peds-FACIT-F) at Week 12
Units on a scalePlaceboPF-04965842 100mg QDPF-04965842 200mg QD
Change From Baseline in Pediatric Functional Assessment of Chronic Illness Therapy Fatigue Scale (Peds-FACIT-F) at Week 122.5 (1.1 to 3.9)4.5 (3.0 to 5.9)4.3 (2.9 to 5.7)
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. TEAEs were AEs that occurred following the start of treatment or AEs increasing in severity during treatment. Treatment-related TEAEs were determined by the investigator.

Time frame:
16 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsPlaceboPF-04965842 100mg QDPF-04965842 200mg QD
All-causality TEAEs505459
Treatment-related TEAEs162031
SecondaryNumber of Participants With Serious Adverse Events (SAEs)

A serious adverse event (SAE) was any untoward medical occurrence at any dose that resulted in death; was life threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect. Treatment-related SAEs were determined by the investigator.

Time frame:
16 weeks
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs)
ParticipantsPlaceboPF-04965842 100mg QDPF-04965842 200mg QD
All-causality SAEs201
Treatment-related SAEs000
SecondaryNumber of Participants Who Discontinued From the Study Due to TEAEs

An AE was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. TEAEs were AEs that occurred following the start of treatment or AEs increasing in severity during treatment. Treatment-related TEAEs were determined by the investigator.

Time frame:
16 weeks
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued From the Study Due to TEAEs
ParticipantsPlaceboPF-04965842 100mg QDPF-04965842 200mg QD
All-causality TEAEs212
Treatment-related TEAEs002
SecondaryNumber of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)

Laboratory tests included hematology (including coagulation panel), clinical chemistry, lipid profile panel, and routine urinalysis. LLN is lower limit of normal. ULN is upper limit of normal.

Time frame:
16 weeks
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)
ParticipantsPlaceboPF-04965842 100mg QDPF-04965842 200mg QD
Hemoglobin (g/dL) <0.8*LLN000
Hematocrit (%) <0.8*LLN000
Erythrocytes (10^6/mm^3) <0.8*LLN000
Reticulocytes (10^3/mm^3) <0.5*LLN000
Reticulocytes (10^3/mm^3) >1.5*ULN000
Ery. Mean Corpuscular Volume (10^-15L) <0.9*LLN110
Ery. Mean Corpuscular Volume (10^-15L) >1.1*ULN000
Ery. Mean Corpuscular Hemoglobin (pg/cell) <0.9*LLN110
Ery. Mean Corpuscular Hemoglobin (pg/cell) >1.1*ULN000
Ery. Mean Corpuscular HGB Concentration (g/dL) <0.9*LLN000
Ery. Mean Corpuscular HGB Concentration (g/dL) >1.1*ULN000
Platelets (10^3/mm^3) <0.5*LLN100
Platelets (10^3/mm^3) >1.75*ULN000
Reticulocytes/Erythrocytes (%) <0.5*LLN000
Reticulocytes/Erythrocytes (%) >1.5*ULN001
Leukocytes (10^3/mm^3) <0.6*LLN000
Leukocytes (10^3/mm^3) >1.5*ULN100
Lymphocytes (10^3/mm^3) <0.8*LLN001
Lymphocytes (10^3/mm^3) >1.2*ULN001
Lymphocytes/Leukocytes (%) <0.8*LLN646
Lymphocytes/Leukocytes (%) >1.2*ULN114
Neutrophils (10^3/mm^3) <0.8*LLN121
Neutrophils (10^3/mm^3) >1.2*ULN653
Neutrophils/Leukocytes (%) <0.8*LLN537
Neutrophils/Leukocytes (%) >1.2*ULN000
Basophils (10^3/mm^3) >1.2*ULN300
Basophils/Leukocytes (%) >1.2*ULN352427
Eosinophils (10^3/mm^3) >1.2*ULN635539
Eosinophils/Leukocytes (%) >1.2*ULN616247
Monocytes (10^3/mm^3) >1.2*ULN100
Monocytes/Leukocytes (%) >1.2*ULN7116
Activated Partial Thromboplastin Time (sec) >1.1*ULN244
Prothrombin Time (sec) >1.1*ULN468
Prothrombin Intl.Normalized Ratio >1.1*ULN000
Bilirubin (mg/dL) >1.5*ULN140
Direct Bilirubin (mg/dL) >1.5*ULN000
Indirect Bilirubin (mg/dL) >1.5*ULN120
Aspartate Aminotransferase (U/L) >3.0*ULN113
Alanine Aminotransferase (U/L) >3.0*ULN031
Gamma Glutamyl Transferase (U/L) >3.0*ULN100
Lactate Dehydrogenase (U/L) >3.0*ULN012
Alkaline Phosphatase (U/L) >3.0*ULN001
Protein (g/dL) <0.8*LLN000
Protein (g/dL) >1.2*ULN001
Albumin (g/dL) <0.8*LLN000
Albumin (g/dL) >1.2*ULN003
Urea Nitrogen (mg/dL) >1.3*ULN000
Creatinine (mg/dL) >1.3*ULN320
Urate (mg/dL) >1.2*ULN241
LDL Cholesterol (mg/dL) >1.2*ULN223
Triglycerides (mg/dL) >1.3*ULN171113
Sodium (mEq/L) <0.95*LLN000
Sodium (mEq/L) >1.05*ULN000
Potassium (mEq/L) <0.9*LLN000
Potassium (mEq/L) >1.1*ULN100
Chloride (mEq/L) <0.9*LLN000
Chloride (mEq/L) >1.1*ULN000
Calcium (mg/dL) <0.9*LLN000
Calcium (mg/dL) >1.1*ULN000
Bicarbonate (mEq/L) <0.9*LLN110
Bicarbonate (mEq/L) >1.1*ULN000
Glucose (mg/dL) <0.6*LLN000
Glucose (mg/dL) >1.5*ULN023
Creatine Kinase (U/L) >2.0*ULN5712
Cholesterol (mg/dL)>1.3*ULN222
HDL Cholesterol (mg/dL) <0.8*LLN000
Urine Specific Gravity (scalar) <1.003000
Urine Specific Gravity (scalar) >1.030010
Urine pH (Scalar) <4.5000
Urine pH (Scalar) >8010
Urine Glucose >=1100
Urine Ketones >=1801
Urine Protein >=1450
Urine Hemoglobin >=1201915
Urine Nitrite >=1010
Urine Leukocyte Esterase >=171417
Urine Erythrocytes (/HPF) >=20875
Urine Leukocytes (/HPF) >=20021
Urine Granular Casts (/LPF) >1100
Urine Hyaline Casts (/LPF) >1211
Urine Bacteria >20000
SecondaryNumber of Participants With Electrocardiogram (ECG) Data Meeting Prespecified Criteria

A 12-lead ECG was obtained using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and corrected QT intervals. All scheduled ECGs were performed after the participant had rested quietly for at least 10 minutes in a supine position. Reading of ECGs were performed by a central reader who has expertise reading and interpreting ECGs in adolescents. The QTcF interval is the only prespecified ECG criteria (Marked prolongation of the QTcF interval to \>500 ms or \>60 ms change from screening ECG); data are presented below.

Time frame:
16 weeks
Reported as:
Count of participants · Participants
Number of Participants With Electrocardiogram (ECG) Data Meeting Prespecified Criteria
ParticipantsPlaceboPF-04965842 100mg QDPF-04965842 200mg QD
QTcF Interval, Single Beat (msec) Value >500000
QTcF Interval, Single Beat (msec) Change From Screening >60000
SecondaryCategorization of Vital Signs Data Meeting Prespecified Criteria

Vital signs (pulse rate, systolic and diastolic blood pressure) were obtained with participant in the seated position, after having sat calmly for at least 5 minutes.

Time frame:
16 weeks
Reported as:
Count of participants · Participants
Categorization of Vital Signs Data Meeting Prespecified Criteria
ParticipantsPlaceboPF-04965842 100mg QDPF-04965842 200mg QD
Diastolic Blood Pressure Value <50mmHg319
Diastolic Blood Pressure Increase From Baseline >= 20mmHg366
Diastolic Blood Pressure Decrease From Baseline >= 20mmHg348
Pulse Rate Value <40 bpm000
Pulse Rate Value >120 bpm000
Systolic Blood Pressure Value <90mmHg474
Systolic Blood Pressure Increase From Baseline >=30mmHg212
Systolic Blood Pressure Decrease From Baseline >=30mmHg212
SecondaryFold Increase of Immunoglobulin G (IgG) Concentrations Against Specific Vaccine Antigens at 4 Weeks Post-Vaccination

The immunogenicity analysis was to evaluate the effect of abrocitinib on immunogenicity to a tetanus, diphtheria and pertussis combination vaccine (Tdap) vaccine in adolescent participants 12 to \<18 years of age with moderate to severe AD. Participants who completed 8 weeks of treatment with study intervention received Tdap at Week 8, and had blood samples collected for the evaluation of immunogenicity to the vaccine at Weeks 8 and 12. The fold increase was defined as the ratio (post-vaccination: pre-vaccination) of concentration values. The geometric mean fold rise (GMFR) is presented below, and was calculated by first arithmetically averaging the logarithmically transformed ratio (post-vaccination: pre-vaccination) values, and then back transformation. A 95% CI for GMFR was constructed by back transformation of the CI for the logarithmically transformed GMFRs computed using the Student's t distribution.

Time frame:
4 weeks post-vaccination with Tdap (Week 12)
Reported as:
Geometric mean · Ratio
Fold Increase of Immunoglobulin G (IgG) Concentrations Against Specific Vaccine Antigens at 4 Weeks Post-Vaccination
RatioPlaceboPF-04965842 100mg QDPF-04965842 200mg QD
Diphtheria IgG Antibody14.00 (6.32 to 30.99)6.51 (2.31 to 18.34)34.61 (6.96 to 172.06)
Filamentous Hemagglutinin IgG15.19 (4.89 to 47.16)11.48 (2.65 to 49.69)22.77 (7.26 to 71.45)
Fimbriae 2/3 IgG1.93 (0.79 to 4.73)1.11 (0.85 to 1.46)1.47 (0.61 to 3.50)
Pertactin IgG54.03 (14.67 to 199.03)15.60 (5.77 to 42.14)60.18 (12.79 to 283.08)
Pertussis Toxin IgG6.94 (1.95 to 24.71)10.17 (4.71 to 21.94)33.16 (5.04 to 218.38)
Tetanus Toxoid IGG AB8.36 (1.62 to 43.18)16.26 (3.52 to 75.11)48.41 (9.01 to 260.09)
SecondaryPlasma PF-04965842 Concentration at Week 8
Time frame:
2 hours pre-dose at Week 8
Reported as:
Mean · ng/mL
Plasma PF-04965842 Concentration at Week 8
ng/mLPF-04965842 100mg QDPF-04965842 200mg QD
Plasma PF-04965842 Concentration at Week 87.882 ± 26.35032.33 ± 76.506
SecondaryPlasma PF-04965842 Concentration at Week 12
Time frame:
2 hours post-dose at Week 12
Reported as:
Mean · ng/mL
Plasma PF-04965842 Concentration at Week 12
ng/mLPF-04965842 100mg QDPF-04965842 200mg QD
Plasma PF-04965842 Concentration at Week 12486.6 ± 403.691271 ± 1000.4

Adverse events

Collected over 16 weeks. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/96 (0%)2/96 (2.1%)42/96 (43.8%)
PF-04965842 100mg QD0/95 (0%)0/95 (0%)40/95 (42.1%)
PF-04965842 200mg QD0/94 (0%)1/94 (1.1%)50/94 (53.2%)
Most frequent serious events
Most frequent serious events
EventPlaceboPF-04965842 100mg QDPF-04965842 200mg QD
AnxietyPsychiatric disorders0/960/951/94
AngioedemaSkin and subcutaneous tissue disorders1/960/950/94
Dermatitis stopicSkin and subcutaneous tissue disorders1/960/950/94
Most frequent other events
Showing 10 of 33
Most frequent other events
EventPlaceboPF-04965842 100mg QDPF-04965842 200mg QD
NauseaGastrointestinal disorders1/967/9517/94
Upper respiratory tract infectionInfections and infestations10/969/9510/94
NasopharyngitisInfections and infestations9/968/958/94
HeadacheNervous system disorders7/965/958/94
FolliculitisInfections and infestations1/967/952/94
DizzinessNervous system disorders1/960/956/94
AcneSkin and subcutaneous tissue disorders1/963/955/94
VomitingGastrointestinal disorders0/964/955/94
PharyngitisInfections and infestations3/965/953/94
Blood creatine phosphokinase increasedInvestigations0/964/954/94

Baseline characteristics

Baseline analysis population included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the intervention they actually received.

Age, Continuous
Age, Continuous(Years)PlaceboPF-04965842 100mg QDPF-04965842 200mg QDTotal
Mean14.8 ± 1.715.1 ± 1.814.7 ± 1.814.9 ± 1.7
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboPF-04965842 100mg QDPF-04965842 200mg QDTotal
Female525038140
Male444556145
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboPF-04965842 100mg QDPF-04965842 200mg QDTotal
Hispanic or Latino25262576
Not Hispanic or Latino656369197
Unknown or Not Reported66012
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboPF-04965842 100mg QDPF-04965842 200mg QDTotal
White565252160
Black or African American39517
Asian32313194
American Indian or Alaska Native1348
Native Hawaiian or Other Pacific Islander1012
Multiracial1012
Not reported2002
08

Study locations

136 sites
  • Clinical Research Center of Alabama, LLC
    Birmingham, Alabama 35244, United States
  • Madera Family Medical Group
    Madera, California 93637, United States
  • Allergy & Asthma Associates of Southern California dba Southern California Research
    Mission Viejo, California 92691, United States
  • UC Davis
    Sacramento, California 95816, United States
  • Moonshine Research Center, Inc.
    Doral, Florida 33166, United States
  • Homestead Research Institute
    Homestead, Florida 33030, United States
  • Olympian Clinical Research
    Largo, Florida 33770, United States
  • Clinical Trials Solutions
    Miami, Florida 33126, United States
  • Global Health Clinical Trials Corp
    Miami, Florida 33135, United States
  • La Salud Research Clinic, Inc.
    Miami, Florida 33155, United States
  • Nicklaus Children's Hospital
    Miami, Florida 33155, United States
  • South Miami Medical & Research Group, Inc.
    Miami, Florida 33155, United States
  • Ciocca Dermatology, PA
    Miami, Florida 33173, United States
  • INTERMED Medical Research Center, Inc
    Miami, Florida 33175, United States
  • Suncoast Research Associates
    Miami, Florida 33184, United States
  • AdventHealth Orlando
    Orlando, Florida 32803, United States
  • AdventHealth Pediatric Dermatology Orlando
    Orlando, Florida 32803, United States
  • AdventHealth Orlando - Investigational Drug Services
    Orlando, Florida 32804, United States
  • Outpatient Service Center-AdventHealth Orlando
    Orlando, Florida 32804, United States
  • Pediatric Outpatient Procedures and Sedation
    Orlando, Florida 32804, United States
  • NeuroSkeletal Imaging
    Orlando, Florida 32806, United States
  • Accel Research Sites - Pure Skin Dermatology & Aesthetics
    Orlando, Florida 32819, United States
  • Accel Research Sites - Nona Pediatric Center
    Orlando, Florida 32829, United States
  • ForCare Clinical Research
    Tampa, Florida 33613, United States
  • Columbus Regional Research Institute
    Columbus, Georgia 31904, United States
  • Meridian Clinical Research, LLC
    Savannah, Georgia 31406, United States
  • Midwest Allergy Sinus Asthma, SC
    Normal, Illinois 61761, United States
  • NorthShore University HealthSystem Dermatology Clinical Trials Unit
    Skokie, Illinois 60077, United States
  • Dawes Fretzin Clinical Research Group, LLC
    Indianapolis, Indiana 46250, United States
  • The South Bend Clinic Center for Research
    South Bend, Indiana 46617, United States
  • Forefront Dermatology S.C.
    Louisville, Kentucky 40202, United States
  • Institute for Asthma and Allergy
    Chevy Chase, Maryland 20815, United States
  • DermAssociates, LLC
    Rockville, Maryland 20850, United States
  • Chesapeake Clinical Research, Inc.
    White Marsh, Maryland 21162, United States
  • Clarkston Skin Research
    Clarkston, Michigan 48346, United States
  • Wayne State University / Integrative Biosciences Center
    Detroit, Michigan 48202, United States
  • Center for Outpatient Health
    Saint Louis, Missouri 63108, United States
  • St. Louis Children's Hospital
    Saint Louis, Missouri 63108, United States
  • St. Louis Children's Hospital
    Saint Louis, Missouri 63110, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Clinical Research Consortium
    Las Vegas, Nevada 89119, United States
  • DermResearch Center of New York, Inc.
    Stony Brook, New York 11790, United States
  • Synexus Clinical Research US, Inc.
    Cincinnati, Ohio 45236, United States
  • University of Oklahoma Health Science Center
    Oklahoma City, Oklahoma 73104, United States
  • Synexus Clinical Research US, Inc.
    Anderson, South Carolina 29621, United States
  • Synexus Clinical Research US, Inc.
    Greer, South Carolina 29651, United States
  • Austin Institute for Clinical Research, Inc.
    Austin, Texas 78705, United States
  • Center for Clinical Studies, LTD.LLP
    Webster, Texas 77598, United States
  • Virginia Clinical Research, Inc
    Norfolk, Virginia 23502, United States
  • West Virginia Research Institute
    Morgantown, West Virginia 26505, United States
  • Children's Hospital of Wisconsin Investigational Drug Service
    Milwaukee, Wisconsin 53226, United States
  • Children's Hospital of Wisconsin Translational Research Unit
    Milwaukee, Wisconsin 53226, United States
  • Australian Clinical Research Network
    Maroubra, New South Wales 2035, Australia
  • The Skin Hospital
    Westmead, New South Wales 2145, Australia
  • The Skin Centre
    Benowa, Queensland 4217, Australia
  • Sinclair Dermatology
    East Melbourne, Victoria (vic) 3002, Australia
  • The Royal Children's Hospital
    Parkville, Victoria 3052, Australia
  • The First Affiliated Hospital of Fujian Medical University, Dermatology Department
    Fuzhou, Fujian 350005, China
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan 410013, China
  • Dermatology Hospital of Jiangxi Province
    Nanchang, Jiangxi 330000, China
  • Shandong Provincial Institute of Dermatology and Venereology & Shandong Provincial Hospital for Skin
    Jinan, Shandong 250022, China
  • Huashan Hospital Fudan University
    Shanghai, Shanghai 200040, China
  • First Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan 650032, China
  • Hangzhou Third Hospital
    Hangzhou, Zhejiang 310009, China
  • The Second Affiliated Hospital of Zhejiang University School of Medicine/Dermatology Dept
    Hangzhou, Zhejiang 310009, China
  • Xin Hua Hospital Affiliated to Shanghai Jiaotong University School of Medicine/Dermatology
    Shanghai, 200092, China
  • Shanghai Dermatology Hospital
    Shanghai, 200443, China
  • Lekarna Na Vaclavskem namesti
    Kutna Hora, 284 01, Czechia
  • Kozni ambulance Kutna Hora, s.r.o
    Kutna Hora, 28401, Czechia
  • Dermamedica S.R.O.
    Nachod, 547 01, Czechia
  • Oblastni nemocnice Nachod
    Nachod, 547 01, Czechia
  • Lekarna u Stribrneho orla
    Nachod, 54701, Czechia
  • Lekarna Cisarska
    Praha 2, 120 00, Czechia
  • Synexus Czech S.R.O.
    Praha 2, 120 00, Czechia
  • Mestska poliklinika Praha
    Praha, 110 00, Czechia
  • Dermatovenerologicka ambulance
    Svitavy, 56802, Czechia
  • Lekarna na Hranicni
    Svitavy, 56802, Czechia
  • Nemocnice Svitavy
    Svitavy, 56825, Czechia
  • Universitaetsklinikum Bonn
    Bonn, NRW 53105, Germany
  • Fachklinik Bad Bentheim Thermalsole- und Schwefelbad Bentheim GmbH
    Bad Bentheim, 48455, Germany
  • Universitaetsklinikum Bonn
    Bonn, 53127, Germany
  • MENSINGDERMA research GmbH
    Hamburg, 22391, Germany
  • Uniklinik Muenster
    Muenster, 48149, Germany
  • Clinexpert Kft.
    Budapest, 1033, Hungary
  • Bugát Pál Kórház, Bőrgyógyászati Szakrendelés
    Gyöngyös, 3200, Hungary
  • Trial Pharma Kft.
    Győr, 9026, Hungary
  • Trial Pharma Kft.
    Kaposvár, 7400, Hungary
  • Borsod-Abaúj-Zemplén Megyei Központi Kórház és Gyermek Gasztroenterológia II. emelet
    Miskolc, 3526, Hungary
  • Trial Pharma Kft.
    Püspökladány, 4150, Hungary
  • Istituto Clinico Humanitas IRCSS - UOC di Dermatologia
    Milano, 20089, Italy
  • Takagi Dermatological Clinic
    Obihiro, Hokkaido 080-0013, Japan
  • Dermatology Shimizu Clinic
    Kobe, Hyogo 657-0846, Japan
  • Noguchi Dermatology Clinic
    Kamimashiki-gun, Kumamoto 861-3101, Japan
  • Yoshioka Dermatology Clinic
    Neyagawa, Osaka 572-0838, Japan
  • Kume Clinic
    Sakai, Osaka 593-8324, Japan
  • Fukuwa Clinic
    Chuo-ku, Tokyo 104-0031, Japan
  • Hoshikuma Dermatology・Allergy Clinic
    Fukuoka, 814-0171, Japan
  • Matsuda Tomoko Dermatological Clinic
    Fukuoka, 819-0167, Japan
  • Aesthetic dermatology clinic of Prof. J. Kisis
    Riga, LV-1003, Latvia
  • Outpatient Clinic Of Ventspils
    Ventspils, LV-3601, Latvia

Showing the first 100 of 136 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Cork MJ, McMichael A, Teng J, Valdez H, Rojo R, Chan G, Zhang F, Myers DE, DiBonaventura M. Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate-to-severe atopic dermatitis: an analysis of patient-reported outcomes. J Eur Acad Dermatol Venereol. 2022 Mar;36(3):422-433. doi: 10.1111/jdv.17792. Epub 2021 Dec 4. PubMed 34743361 ↗
  • Eichenfield LF, Flohr C, Sidbury R, Siegfried E, Szalai Z, Galus R, Yao Z, Takahashi H, Barbarot S, Feeney C, Zhang F, DiBonaventura M, Rojo R, Valdez H, Chan G. Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial. JAMA Dermatol. 2021 Oct 1;157(10):1165-1173. doi: 10.1001/jamadermatol.2021.2830. Erratum In: JAMA Dermatol. 2021 Oct 1;157(10):1246. doi: 10.1001/jamadermatol.2021.4398. PubMed 34406366 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Apr 2020, 13 months.

Results were first posted in Jun 2021, 1 year 1 month after primary completion.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 13 months is below that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2019
First posted
Jan 8, 2019
StartActual
Feb 18, 2019
Primary completionActual
Apr 8, 2020
CompletionActual
Apr 8, 2020
Results first posted
Jun 4, 2021
Last update
Apr 13, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03796676
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jan 8, 2019
Start date
Feb 18, 2019
Primary completion
Apr 8, 2020
Completion
Apr 8, 2020
Results posted
Jun 4, 2021
Last update
Apr 13, 2022

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abrocitinib

Start the discussion